467 related articles for article (PubMed ID: 17237886)
21. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
22. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
Meier-Kriesche HU
Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
[TBL] [Abstract][Full Text] [Related]
25. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome after early cyclosporine withdrawal in kidney transplantation: ten years after.
Tabibzadeh N; Glowacki F; Frimat M; Elsermans V; Provôt F; Lionet A; Gnemmi V; Hertig A; Noël C; Hazzan M
Clin Transplant; 2016 Nov; 30(11):1480-1487. PubMed ID: 27623348
[TBL] [Abstract][Full Text] [Related]
27. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
28. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
[TBL] [Abstract][Full Text] [Related]
30. Eight-year outcomes of 'the Cairo Kidney Centre sequential protocol'.
Fayad T; William E; Tawfik N; Habashy B; Abou-Youssef HS; Shokry S; Khalil S; Morsy A; Barsoum R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():23-9. PubMed ID: 25894123
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
[TBL] [Abstract][Full Text] [Related]
32. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
[TBL] [Abstract][Full Text] [Related]
33. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
34. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
35. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
36. Calcineurin inhibitor minimization protocols in liver transplantation.
Farkas SA; Schnitzbauer AA; Kirchner G; Obed A; Banas B; Schlitt HJ
Transpl Int; 2009 Jan; 22(1):49-60. PubMed ID: 19121146
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation.
Haller M; Oberbauer R
Transpl Int; 2009 Jan; 22(1):69-77. PubMed ID: 18764837
[TBL] [Abstract][Full Text] [Related]
38. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
39. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
